RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
RHYTHM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$88.23+2.06 (+2.39%)
Close on Oct 19, 2026
- Market cap
- $6.05B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
77M of 69M shares
Institutional holders
303
64 new, 41 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 52 sales
Net sold $40.09M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Kolchinsky | 6,666,837 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Baker Bros. Advisors LP | 5,604,483 | 8.90% | 13G (passive) amendment | Mar 31, 2025 |
| Rajeev Shah | 5,561,359 | 8.70% | 13G (passive) amendment | Jun 30, 2025 |
| BlackRock, Inc. | 4,364,700 | 6.90% | 13G (passive) amendment | Mar 31, 2025 |
| JPMorgan Chase & Co. | 3,563,667 | 5.10% | 13G (passive) | Sep 30, 2026 |
| Perceptive Advisors LLC | 3,519,626 | 5.10% | 13G (passive) amendment | Mar 31, 2026 |
| Primecap Management Co/Ca/ | 3,478,669 | 5.21% | 13G (passive) amendment | Dec 31, 2025 |
| Vanguard Capital Management | 3,432,949 | 5.02% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RYTM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 6,666,837 | 9.68% | $740.22M | – | 6.43% |
| BlackRock, Inc. | 6,156,902 | 8.94% | $683.60M | −80,249 | 0.01% |
| Baker Bros. Advisors LP | 5,604,483 | 8.14% | $622.27M | – | 3.12% |
| Primecap Management Co/Ca/ | 3,168,853 | 4.60% | $351.84M | −248,656 | 0.21% |
| Vanguard Portfolio Management LLC | 3,136,895 | 4.56% | $348.29M | +96,177 | 0.02% |
| Vanguard Capital Management LLC | 3,005,977 | 4.37% | $333.75M | +38,152 | 0.01% |
| JPMorgan Chase & Co | 2,652,746 | 3.85% | $292.18M | +1,099,102 | 0.02% |
| Perceptive Advisors LLC | 2,586,295 | 3.76% | $287.16M | +212,500 | 4.31% |
| State Street Corp | 2,573,529 | 3.74% | $285.73M | +301,678 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 2,566,171 | 3.73% | $284.92K | +911,295 | 0.03% |
| Westfield Capital Management Co LP | 2,208,595 | 3.21% | $245.22M | +279,472 | 0.80% |
| Goldman Sachs Group Inc | 2,126,502 | 3.09% | $236.11M | +161,070 | 0.02% |
| Federated Hermes, Inc. | 1,785,716 | 2.59% | $198.27M | +499,413 | 0.29% |
| Polar Capital Holdings Plc | 1,663,632 | 2.42% | $184.71M | +48,046 | 0.44% |
| Geode Capital Management, LLC | 1,533,698 | 2.23% | $170.32M | +117,429 | 0.01% |
| Capital Research Global Investors | 1,532,303 | 2.23% | $170.13M | +416,843 | 0.02% |
| Citadel Advisors LLC | 1,263,652 | 1.84% | $140.30M | −154,967 | 0.02% |
| Checkpoint Capital L.P. | 1,186,000 | 1.72% | $131.68M | −41,200 | 33.79% |
| Siren, L.L.C. | 1,136,275 | 1.65% | $126.16M | +410,764 | 2.55% |
| Morgan Stanley | 1,112,240 | 1.62% | $123.49M | +408,262 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 303 | 77M | 100.0% | 64 / 105 | 101 / 41 | 10M | 6M |
| Q1 2026 | 285 | 74M | 100.0% | 63 / 102 | 89 / 54 | 15M | 8M |
| Q4 2025 | 281 | 73M | 100.0% | 58 / 106 | 90 / 39 | 8M | 7M |
| Q3 2025 | 264 | 72M | 100.0% | 57 / 99 | 82 / 17 | 10M | 5M |
| Q2 2025 | 227 | 67M | 96.9% | 33 / 93 | 74 / 33 | 8M | 6M |
| Q1 2025 | 228 | 65M | 94.3% | 45 / 87 | 69 / 19 | 8M | 7M |
| Q4 2024 | 203 | 65M | 94.3% | 52 / 67 | 53 / 24 | 4M | 7M |
| Q3 2024 | 176 | 68M | 98.4% | 31 / 60 | 55 / 19 | 11M | 6M |
| Q2 2024 | 165 | 70M | 100.0% | 24 / 62 | 55 / 24 | 5M | 5M |
| Q1 2024 | 167 | 69M | 99.8% | 25 / 64 | 53 / 26 | 6M | 5M |
| Q4 2023 | 168 | 67M | 97.7% | 44 / 42 | 63 / 19 | 8M | 9M |
| Q3 2023 | 143 | 68M | 99.3% | 39 / 48 | 39 / 12 | 8M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RYTM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,176,750 | 3.16% | $241.68M | 0.01% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 1,967,269 | 2.86% | $195.25M | 2.64% | Jul 31, 2026 |
| SMALLCAP World Fund Inc | 1,707,348 | 2.48% | $189.57M | 0.20% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,572,293 | 2.28% | $174.57M | 0.09% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,416,703 | 2.06% | $157.30M | 0.19% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,161,672 | 1.69% | $128.98M | 1.20% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund | 1,026,365 | 1.49% | $101.87M | 2.07% | Jul 31, 2026 |
| PRIMECAP Odyssey Growth Fund | 1,008,902 | 1.47% | $100.13M | 1.65% | Jul 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 905,995 | 1.32% | $100.59M | 0.21% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 779,815 | 1.13% | $86.58M | 0.59% | Jun 30, 2026 |
| JPMorgan Mid Cap Growth Fund | 747,736 | 1.09% | $83.02M | 0.63% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 715,692 | 1.04% | $79.46M | 0.08% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 610,000 | 0.89% | $60.54M | 2.13% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 603,209 | 0.88% | $59.87M | 0.18% | Jul 31, 2026 |
| Vanguard Explorer Fund | 559,749 | 0.81% | $55.56M | 0.25% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David P. Meeker | President and CEO, Director | 289,258 | 0.42% | Sep 14, 2026 |
| Hunter C. Smith | Chief Financial Officer | 114,024 | 0.17% | Sep 1, 2026 |
| Manher Joshi | Chief Medical Officer | – | – | Aug 18, 2026 |
| Joseph Shulman | Chief Technical Officer | 20,994 | 0.03% | Aug 17, 2026 |
| Alastair Garfield | Chief Scientific Officer | 3,095 | 0.00% | Aug 17, 2026 |
| Yann Mazabraud | EVP, Head of International | 105,750 | 0.15% | Aug 14, 2026 |
| Jennifer Kayden Lee | EVP, Head of North America | 75,834 | 0.11% | Aug 14, 2026 |
| Christopher Paul German | Corporate Controller & CAO | 1,888 | 0.00% | May 19, 2026 |
| Pamela J. Cramer | Chief Human Resources Officer | 29,376 | 0.04% | Feb 13, 2026 |
| Lynn A. Tetrault | Director | 11,712 | 0.02% | Jun 25, 2026 |
| Stuart A. Arbuckle | Director | 11,712 | 0.02% | Jun 25, 2026 |
| David W. J. McGirr | Director | 11,712 | 0.02% | Jun 25, 2026 |
| Christophe Jean | Director | 11,712 | 0.02% | Jun 25, 2026 |
| Jennifer L. Good | Director | 11,712 | 0.02% | Jun 25, 2026 |
| Kimberly J. Popovits | Director | – | – | Apr 3, 2026 |
| Edward T. Mathers | Director | 21,168 | 0.03% | Mar 16, 2026 |
| Camille L. Bedrosian | Director | 7,000 | 0.01% | Jun 26, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David P. Meeker President and CEO, Director | Sep 14, 2026 | Option exercise | +50,000 | $6.05 | $302.50K | 289,258 |
| David P. Meeker President and CEO, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −1,817 | $104.55 | $189.97K | 241,558 |
| David P. Meeker President and CEO, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −8,698 | $103.43 | $899.63K | 243,375 |
| David P. Meeker President and CEO, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −30,746 | $102.35 | $3.15M | 252,073 |
| David P. Meeker President and CEO, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −6,439 | $101.75 | $655.17K | 282,819 |
| David P. Meeker President and CEO, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −2,300 | $105.19 | $241.94K | 239,258 |
| Hunter C. Smith Chief Financial Officer | Aug 31, 2026 | Sale(10b5-1 plan) | −28,188 | $106.20 | $2.99M | 114,024 |
| Hunter C. Smith Chief Financial Officer | Aug 31, 2026 | Option exercise | +57,187 | $25.79 | $1.47M | 176,798 |
| Hunter C. Smith Chief Financial Officer | Aug 31, 2026 | Sale(10b5-1 plan) | −23,072 | $104.59 | $2.41M | 153,726 |
| Hunter C. Smith Chief Financial Officer | Aug 31, 2026 | Sale(10b5-1 plan) | −11,514 | $105.37 | $1.21M | 142,212 |
| Alastair Garfield Chief Scientific Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −3,400 | $118.28 | $402.15K | 3,095 |
| Alastair Garfield Chief Scientific Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −2,007 | $116.11 | $233.03K | 8,051 |
| Alastair Garfield Chief Scientific Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −800 | $119.17 | $95.34K | 2,295 |
| Alastair Garfield Chief Scientific Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −1,556 | $117.08 | $182.18K | 6,495 |
| Joseph Shulman Chief Technical Officer | Aug 13, 2026 | Option exercise | +2,024 | $6.80 | $13.76K | 20,994 |
| Joseph Shulman Chief Technical Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −5,079 | $119.75 | $608.21K | 15,915 |
| Jennifer Kayden Lee EVP, Head of North America | Aug 13, 2026 | Option exercise | +21,601 | $6.80 | $146.89K | 75,834 |
| Jennifer Kayden Lee EVP, Head of North America | Aug 13, 2026 | Option exercise | +35,000 | $24.29 | $850.15K | 54,233 |
| Jennifer Kayden Lee EVP, Head of North America | Aug 13, 2026 | Sale(10b5-1 plan) | −75,834 | $117.38 | $8.90M | 0 |
| Yann Mazabraud EVP, Head of International | Aug 12, 2026 | Sale(10b5-1 plan) | −3,605 | $114.70 | $413.49K | 105,750 |
| Yann Mazabraud EVP, Head of International | Aug 12, 2026 | Option exercise | +46,625 | $6.80 | $317.05K | 112,655 |
| Yann Mazabraud EVP, Head of International | Aug 12, 2026 | Sale(10b5-1 plan) | −2,300 | $111.80 | $257.14K | 110,355 |
| Yann Mazabraud EVP, Head of International | Aug 12, 2026 | Sale(10b5-1 plan) | −1,000 | $112.86 | $112.86K | 109,355 |
| Yann Mazabraud EVP, Head of International | Aug 12, 2026 | Sale(10b5-1 plan) | −17,319 | $117.47 | $2.03M | 55,655 |
| Yann Mazabraud EVP, Head of International | Aug 12, 2026 | Sale(10b5-1 plan) | −18,208 | $116.49 | $2.12M | 72,974 |
| Yann Mazabraud EVP, Head of International | Aug 12, 2026 | Sale(10b5-1 plan) | −14,568 | $115.43 | $1.68M | 91,182 |
| Alastair Garfield Chief Scientific Officer | Jul 1, 2026 | Tax withholding | −2,150 | $110.41 | $237.38K | 10,058 |
| Alastair Garfield Chief Scientific Officer | Jul 1, 2026 | Option exercise | +4,445 | – | – | 12,208 |
| Christophe Jean Director | Jun 23, 2026 | Option exercise | +4,712 | – | – | 11,712 |
| David W. J. McGirr Director | Jun 23, 2026 | Option exercise | +4,712 | – | – | 11,712 |
| Stuart A. Arbuckle Director | Jun 23, 2026 | Option exercise | +4,712 | – | – | 11,712 |
| Jennifer L. Good Director | Jun 23, 2026 | Option exercise | +4,712 | – | – | 11,712 |
| Lynn A. Tetrault Director | Jun 23, 2026 | Option exercise | +4,712 | – | – | 11,712 |
| Lynn A. Tetrault Director | Jun 22, 2026 | Option exercise | +37,000 | $28.27 | $1.05M | 44,000 |
| Lynn A. Tetrault Director | Jun 22, 2026 | Sale(10b5-1 plan) | −37,000 | $100.32 | $3.71M | 7,000 |
| Hunter C. Smith Chief Financial Officer | May 18, 2026 | Option exercise | +3,000 | $17.87 | $53.61K | 119,611 |
| Christopher Paul German Corporate Controller & CAO | May 15, 2026 | Option exercise | +1,687 | $56.69 | $95.64K | 1,888 |
| Christopher Paul German Corporate Controller & CAO | May 15, 2026 | Option exercise | +1,349 | $49.23 | $66.41K | 3,237 |
| Christopher Paul German Corporate Controller & CAO | May 15, 2026 | Sale | −4,643 | $92.21 | $428.13K | 0 |
| Christopher Paul German Corporate Controller & CAO | May 15, 2026 | Option exercise | +1,406 | $17.97 | $25.27K | 4,643 |
| Yann Mazabraud EVP, Head of International | Apr 1, 2026 | Option exercise | +12,875 | – | – | 66,030 |
| Edward T. Mathers Director | Mar 12, 2026 | Other | +4,199 | – | – | 14,168 |
| Christopher Paul German Corporate Controller & CAO | Mar 4, 2026 | Option exercise | +1,500 | $17.97 | $26.96K | 5,753 |
| Christopher Paul German Corporate Controller & CAO | Mar 4, 2026 | Sale | −5,614 | $89.56 | $502.79K | 160 |
| Edward T. Mathers Director | Mar 2, 2026 | Other | +4,198 | – | – | 9,969 |
| Hunter C. Smith Chief Financial Officer | Mar 2, 2026 | Option exercise | +6,099 | $6.80 | $41.47K | 116,611 |
| Christopher Paul German Corporate Controller & CAO | Mar 1, 2026 | Tax withholding | −342 | $94.94 | $32.47K | 4,253 |
| Christopher Paul German Corporate Controller & CAO | Mar 1, 2026 | Option exercise | +1,162 | – | – | 4,595 |
| Hunter C. Smith Chief Financial Officer | Feb 19, 2026 | Sale(10b5-1 plan) | −585 | $103.28 | $60.42K | 110,512 |
| Hunter C. Smith Chief Financial Officer | Feb 19, 2026 | Sale(10b5-1 plan) | −800 | $102.10 | $81.68K | 111,097 |
| Hunter C. Smith Chief Financial Officer | Feb 19, 2026 | Sale(10b5-1 plan) | −1,692 | $100.92 | $170.76K | 111,897 |
| Hunter C. Smith Chief Financial Officer | Feb 19, 2026 | Sale(10b5-1 plan) | −1,308 | $100.27 | $131.15K | 113,589 |
| Hunter C. Smith Chief Financial Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −200 | $103.84 | $20.77K | 114,897 |
| Hunter C. Smith Chief Financial Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −1,200 | $99.42 | $119.30K | 117,266 |
| Hunter C. Smith Chief Financial Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −1,069 | $103.00 | $110.11K | 115,097 |
| Hunter C. Smith Chief Financial Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −900 | $101.70 | $91.53K | 116,166 |
| Hunter C. Smith Chief Financial Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −200 | $100.52 | $20.10K | 117,066 |
| Yann Mazabraud EVP, Head of International | Feb 14, 2026 | Option exercise | +10,000 | – | – | 53,155 |
| Hunter C. Smith Chief Financial Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −292 | $96.26 | $28.11K | 119,766 |
| Hunter C. Smith Chief Financial Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −400 | $97.67 | $39.07K | 119,366 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Meeker David Director, Officer | Sep 14, 2026 | 50,000 | $5.24M | Sep 14, 2026 | Exercise of Stock Options |
| Smith Hunter Officer | Aug 31, 2026 | 62,774 | $6.73M | Aug 31, 2026 | Exercise of Stock Options |
| Kayden Lee Jennifer Officer | Aug 13, 2026 | 75,834 | $8.92M | Aug 13, 2026 | Exercise of Stock Options |
| J. Shulman Joseph Officer | Aug 13, 2026 | 5,079 | $597.29K | Aug 13, 2026 | Exercise of Stock Options |
| Garfield Alastair Officer | Aug 13, 2026 | 7,763 | $912.93K | Aug 13, 2026 | Restricted Stock Units |
| Mazabraud Yann Officer | Aug 12, 2026 | 57,000 | $6.43M | Aug 12, 2026 | Exercise of Stock Options |
| Cramer Pamela Officer | Aug 11, 2026 | 11,406 | $1.32M | Aug 11, 2026 | Exercise of Stock Options |
| Cramer Pamela Officer | Aug 10, 2026 | 3,520 | $407.02K | Aug 10, 2026 | Exercise of Stock Options |
| Tetrault Lynn Director | Jun 22, 2026 | 37,000 | $3.58M | Jun 22, 2026 | Exercise of Stock Options |
| L. Bedrosian Camille Director | Mar 4, 2026 | 64,540 | $5.85M | Mar 4, 2026 | Exercise of options under a registered plan |
| L. Bedrosian Camille Director | Mar 3, 2026 | 35,460 | $3.21M | Mar 3, 2026 | Exercise of options under a registered plan |
| Smith Hunter Officer | Feb 5, 2026 | 18,406 | $1.99M | Feb 5, 2026 | Restricted Stock Units |
| Smith Hunter Officer | Feb 4, 2026 | 3,247 | $351.62K | Feb 4, 2026 | Restricted Stock Units |
| Cramer Pamela Officer | Dec 11, 2025 | 3,350 | $350.98K | Dec 11, 2025 | Exercise of Stock Options |
| Cramer Pamela Officer | Nov 20, 2025 | 3,350 | $345.55K | Nov 20, 2025 | Exercise of Stock Options |